We postulated that if loss of cyclin D2/CDK4 activity in β cells is a primary cause of diabetes in IRS2-null mice, then activating CDK4 in vivo (22) might counteract the diabetogenic phenotype in these mice. This evidence concerns the gene CDK4 and diabetes mellitus.